Krintel and colleagues carried out a double-blind placebo-controlled study on 180 patients with early RA, 89 of whom were treated with the anti-TNFα agent adalimumab and MTX and 91 with placebo- in combination with MTX. This evidence concerns the gene TNF and rheumatoid arthritis.